We’re pleased to announce we have successfully passed the TGO93 and TGO100 mandatory tests for our first commercial export crop. TGO93 and TGO100 specify the standard for quality requirements for medicinal cannabis products. Implemented by the Therapeutic Goods Administration (TGA), these standards ensure all medicinal cannabis manufacturers provide the highest quality and reliability in therapeutics goods on the market. We’re firmly on course for our first European export by the end of this year.
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >